Agreement with specialist life science and diagnostic labs distributor expands global operational reach and market penetration New distribution channels to
Initial agreement to incorporate Atelerix’s non-cryogenic cell preservation technology into international freight and logistics services for drug discovery and clinical
Abstract Contract Research Organisations (CROs) are increasingly adopting organoid models for drug discovery, toxicology, and preclinical testing. These three-dimensional cellular
By Sophie Reay Organoids are three-dimensional (3D) tissue cultures derived from stem cells that self-organise into structures that closely
Sunil Shah and Dr Catherine Elton join Atelerix’s Board to drive global commercial expansion Industry-leaders Sunil Shah (CEO, o2h
By Sophie Reay Organoids are miniature, three-dimensional (3D) tissue cultures that mimic the structure and function of specific organs. They
Securing research funding is a competitive process. Review panels look for more than just sound science – they’re also seeking
By Sophie Reay, Historically, preclinical testing on animal models formed a critical step in the drug discovery and development pipeline,
As the global biotechnology sector works to extend the reach of life-saving mRNA vaccines, a persistent challenge remains: the carbon-intensive,
At Atelerix, we’re proud to support pioneering work that translates innovative science into real-world patient impact. A recent clinical milestone
Partnership with specialist life science distributor establishes sales channel in high-demand market and strengthens global network Hypothermic preservation technology eliminates
We’re thrilled to share some seriously good news: Atelerix has been shortlisted not once, but twice for the Medilink Healthcare
